2-pyridone derivatives for the treatment of disease or...

Details 2-pyridone derivatives for the treatment of disease or... 2-pyridone derivatives for the treatment of disease or...

2011-08-16

2011-08-16

Andres, Janet L (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S270400, C546S275400, C546S272400, C514S342000, C514S341000

Reexamination Certificate

active

07998984

ABSTRACT:
The invention provides compounds of formulawherein R1, R3, R4, R5, R6, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.

REFERENCES:
patent: 4181658 (1980-01-01), Hitzel et al.
patent: 4186200 (1980-01-01), Kubo et al.
patent: 5441960 (1995-08-01), Bernstein et al.
patent: 5521179 (1996-05-01), Bernstein et al.
patent: 6028081 (2000-02-01), Sada et al.
patent: 6977266 (2005-12-01), Tada et al.
patent: 6979690 (2005-12-01), Gymer et al.
patent: 2004/0082619 (2004-04-01), Tada et al.
patent: 2004/0235761 (2004-11-01), Furuta et al.
patent: 2005/0101590 (2005-05-01), Yasui et al.
patent: 2006/0021169 (2006-02-01), Choo
patent: 2006/0052411 (2006-03-01), Tada et al.
patent: 2006/0100249 (2006-05-01), Smith
patent: 2006/0270666 (2006-11-01), Bladh et al.
patent: 2007/0213323 (2007-09-01), Imogai et al.
patent: 2009/0131486 (2009-05-01), Hansen et al.
patent: 2009/0209555 (2009-08-01), Hansen et al.
patent: 2010/0216843 (2010-08-01), Briggner et al.
patent: 0008864 (1980-03-01), None
patent: 1357111 (2003-10-01), None
patent: 1465626 (2004-10-01), None
patent: 2383326 (2003-06-01), None
patent: 2392910 (2004-03-01), None
patent: 2-152966 (1990-06-01), None
patent: 98/24780 (1998-06-01), None
patent: 02/053543 (2002-07-01), None
patent: WO-03/015798 (2003-02-01), None
patent: 1300396 (2003-04-01), None
patent: WO 03/047577 (2003-06-01), None
patent: WO-03/047577 (2003-06-01), None
patent: WO-03/070277 (2003-08-01), None
patent: WO 2004/020410 (2004-03-01), None
patent: WO 2004/043924 (2004-05-01), None
patent: 2005/021512 (2005-03-01), None
patent: WO 2005/021509 (2005-03-01), None
patent: WO 2005/026123 (2005-03-01), None
patent: WO 2005/026124 (2005-03-01), None
patent: 2005/082864 (2005-09-01), None
patent: WO 2005/080372 (2005-09-01), None
patent: WO-2006/004636 (2006-01-01), None
patent: WO-2006/030032 (2006-03-01), None
patent: 2006/082412 (2006-08-01), None
patent: WO 2006/098683 (2006-09-01), None
patent: WO 2006/098684 (2006-09-01), None
patent: WO-2006/116713 (2006-11-01), None
patent: 2006/136857 (2006-12-01), None
patent: 2007/107706 (2007-09-01), None
patent: 2007/129060 (2007-11-01), None
patent: 2007/129963 (2007-11-01), None
patent: 2008/030158 (2008-03-01), None
patent: 2008/104752 (2008-09-01), None
patent: WO-2008/104752 (2008-09-01), None
patent: 2009/058076 (2009-05-01), None
patent: 2009/061271 (2009-05-01), None
patent: WO-2010/094964 (2010-08-01), None
Bauer and Weber, Justus liebigs Annalen der Chemie, 1972, vol. 762, pp. 73-82. “Close compound but not within scope!”
Beilstein Institute for Organic Chemistry, XP002481053 & KHIM Geterotsikl Soedin vol. 34(1) 1998, pp. 73-76.
Chughtai, et al., J. Aerosol Med., Dec. 1, 2004, 17(4): 289-298.
Europ. Resp. Soc., Feb. 13, 2007, http://www.newtocopd.com/currentaffairsnews/list751—item17680.aspx, downloaded Jan. 16, 2008.
Friedman, Clinical Cornerstone, COPD, vol. 5, No. 1, 45-51, 2004.
Harayama et al, JCS Perkin I, 1987, 75-83.
Ohbayashi, Expert Opinion on Investigational Drugs, 2002, vol. 11(7), pp. 965-980. NEI and diseases.
Ohbayashi, H, Expert Opinion on Therapeutic Patents, 2005, vol. 15(7), pp. 759-771.
Ohbayashi, The Investigational Drugs Journal, 2002, vol. 5(9), pp. 910-923. NEI and diseases.
Okayama, et al., J. Anesth (2006) 20;6-10.
Sato et al., Surgical Oncology, 2006, vol. 15, pp. 217-222. NEI and diseases.
Shimizu, et al., Am. J. Respir. Crit. Care Med., vol. 161, #5, May 2000, 1648-1654.
STN International, File CAPLUS, CAPLUS accession No. 1990:611864, Document No. 113:211864, Otsuka Pharmaceutical Co., Ltd.: “4-Hydroxycarbostyrils as anti-inflammatory and antiallergy agents”; & JP, A2, 02152966, 19900612.
STN International, File CAPLUS, CAPLUS accession No. 1995:456529, Document No. 123:198678, Ukrainets, I.V. et al; “4-Hydroxy-2-quinolones. 23. N-(2-Thiazolyl)amides of 1-substituted 4-hydroxy-2oxoquinoline-3-carboxylic acids—a new group of potential anti-inflammatory drugs”: & Khimiya Geterotsiklicheskikh Soedinenii (1994), (10), 1397-9.
Ukrainets et al. “4-Hydroxy-2-quinolones.23.N-(2-Thiazolyl)amides of 1-substituted 4-hydroxy-2-oxoquinoline-3-carboxylic acids—a new group of potential antiinflammatory drugs” Chemistry of Heterocyclic Compounds, A translation of Khimiya Geterotsiklicheskikh Soedinenii, 30(10): 1211-1213 (1994).
Wright, et al., Eur. Respir. J. 2003; 22:77-81.
Zeiher et al, Critical Care Medicine, 2002, vol. 30(5), suppl. S281 to S287. NEI and diseases.
Eistert et al., “Reactions of Quinones and α-Dicarbonyl Compounds with Diazoalkanes, XXIV. Synthesis and Reactions of Substituted Pyrroline-2,3-Diones with Diazoalkanes”,Justus Liebigs Annalen der Chemie, vol. 6, pp. 1023-1030 (1976).
U.S. Appl. No. 10/569,923, office action dated Apr. 9, 2008.
U.S. Appl. No. 10/569,923, office action dated Dec. 12, 2008.
U.S. Appl. No. 10/534,720, restriction requirement dated Feb. 28, 2008.
U.S. Appl. No. 10/534,720, office action dated Jun. 23, 2008.
U.S. Appl. No. 10/534,720, office action dated Jan. 2, 2009.
U.S. Appl. No. 10/534,720, interview summary dated Jul. 14, 2009.
U.S. Appl. No. 10/569,571, office action dated Sep. 29, 2008.
U.S. Appl. No. 10/569,571, office action dated Mar. 16, 2009.
U.S. Appl. No. 10/569,571, interview summary dated Sep. 28, 2009.
U.S. Appl. No. 10/572,640, office action dated Jan. 21, 2009.
U.S. Appl. No. 10/572,640, interview summary dated Aug. 4, 2009.
U.S. Appl. No. 10/572,706, restriction requirement dated Oct. 29, 2009.
U.S. Appl. No. 10/572,706, non-final rejection dated Feb. 17, 2010.
U.S. Appl. No. 10/572,706, ex-parte quayle action dated Jul. 21, 2010.
U.S. Appl. No. 10/572,706, interview summary dated Nov. 5, 2010.
U.S. Appl. No. 10/572,706, notice of allowance dated Nov. 5, 2010.

Affiliated with

Also associated with

Rating

2-pyridone derivatives for the treatment of disease or... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2-pyridone derivatives for the treatment of disease or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-pyridone derivatives for the treatment of disease or... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2671898